Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show an additional benefit for the drugs evaluated.
The answer is “yes” in both cases: for the combination of trifluridine/tipiracil with bevacizumab in adults with metastatic colorectal cancer who have already received two cancer therapies, the institute found an indication of a non-quantifiable, but at least considerable, additional clinical benefit compared to the appropriate comparative therapy.
